# A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients

> **NCT01649388** · PHASE2 · WITHDRAWN · sponsor: **Talaris Therapeutics Inc.**

## Conditions studied

- Kidney Transplantation

## Interventions

- **BIOLOGICAL:** FCR001

## Key facts

- **NCT ID:** NCT01649388
- **Lead sponsor:** Talaris Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-10-15
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-02-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study terminated by sponsor
- **Last updated:** 2023-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01649388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01649388, "A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01649388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*